These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21063165)

  • 1. [Two cases of pellagra associated with chemotherapy of docetaxel, estramustine, dexamethasone].
    Yokomizo Y; Fujikawa A; Tajiri T; Ota J; Yumura Y; Moriyama M; Mouri S
    Hinyokika Kiyo; 2010 Oct; 56(10):585-8. PubMed ID: 21063165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Low-dose docetaxel, estramustine and dexamethasone combination chemotherapy for hormone-refractory prostate cancer].
    Kobayashi K; Yokonishi T; Ito Y; Matsumoto T; Umemoto S; Osaka K; Nakamura M; Onuki T; Komiya A; Ohgo Y; Sakai N; Noguchi S; Kishi H; Yokomizo Y; Kawai M; Okajima K; Tajiri T; Fujikawa A; Ohta J; Yumura Y; Moriyama M
    Hinyokika Kiyo; 2010 Apr; 56(4):203-7. PubMed ID: 20448443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
    Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
    BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
    Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
    Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy.
    Du J; Yang Q; Chen XS; Tian J; Yao X
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1055-61. PubMed ID: 24043138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
    Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
    N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Optimal treatment for elderly high-risk prostate cancer patients].
    Soga N; Sugimura Y
    Gan To Kagaku Ryoho; 2007 Mar; 34(3):387-92. PubMed ID: 17353629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combination therapy with estramustine and docetaxel for hormone refractory prostate cancer].
    Kanno T; Shibasaki N; Tsuji Y; Taki Y; Takeuchi H
    Hinyokika Kiyo; 2004 Aug; 50(8):521-4. PubMed ID: 15471069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemotherapy with low-dose docetaxel and estramustine phosphate in patient with liver dysfunction due to liver metastases of hormone-refractory prostate cancer : a case report].
    Miyake M; Nakaigawa N; Kita K; Yanagisawa M; Terao H; Sano F; Murakami T; Makiyama K; Ogawa T; Uemura H; Yao M; Kubota Y
    Hinyokika Kiyo; 2010 Jan; 56(1):45-8. PubMed ID: 20104010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-finding study of weekly docetaxel plus estramustine in patients with hormone-refractory metastatic prostate cancer.
    Coccaro M; Tartarone A; Romano G; Ardito R; Di Renzo N
    Tumori; 2005; 91(4):314-6. PubMed ID: 16277095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Meluch AA; Spigel DR; Yost K; Meng C; Greco FA
    Clin Genitourin Cancer; 2006 Mar; 4(4):287-92. PubMed ID: 16729913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.
    Fizazi K; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houedé N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Lagrange JL; Chinet-Charrot P; Linassier C; Deplanque G; Beuzeboc P; Geneve J; Davin JL; Tournay E; Culine S
    Eur J Cancer; 2012 Jan; 48(2):209-17. PubMed ID: 22119204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
    Wilding G; Soulie P; Trump D; Das-Gupta A; Small E
    Cancer; 2006 May; 106(9):1917-24. PubMed ID: 16568471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer.
    Sinibaldi VJ; Carducci M; Laufer M; Eisenberger M
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):45-8. PubMed ID: 10604269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
    J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
    Kattan JG; Farhat FS; Chahine GY; Nasr FL; Moukadem WT; Younes FC; Yazbeck NJ; Ghosn MG;
    Invest New Drugs; 2008 Feb; 26(1):75-9. PubMed ID: 17846704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
    Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
    Dawson NA; Halabi S; Ou SS; Biggs DD; Kessinger A; Vogelzang N; Clamon GH; Nanus DM; Kelly WK; Small EJ;
    Clin Genitourin Cancer; 2008 Sep; 6(2):110-6. PubMed ID: 18824434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials.
    Zhang C; Jing T; Wang F; Gao X; Xu C; Sun Y
    Actas Urol Esp; 2014 Apr; 38(3):184-91. PubMed ID: 24507454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.